AM 1882
Alternative Names: AM-1882Latest Information Update: 08 Jun 2022
At a glance
- Originator Amgen
- Class Antineoplastics; Small molecules
- Mechanism of Action KIF18A protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer; Ovarian cancer
Most Recent Events
- 08 Apr 2022 Preclinical trials in Breast cancer in USA (unspecified route)
- 08 Apr 2022 Preclinical trials in Ovarian cancer in USA (unspecified route)
- 08 Apr 2022 Pharmacodynamics and adverse events data from a preclinical trial in ovarian cancer and breast cancer presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)